Hyperthyroidism / Graves' Disease
Autoimmune thyroid overactivity causing systemic metabolic excess. MSC therapy modulates TSH-receptor autoimmunity and reduces thyroid inflammation.
Graves' disease is the most common cause of hyperthyroidism, accounting for approximately 70–80% of cases. It is driven by stimulating autoantibodies against the thyroid-stimulating hormone receptor (TRAb/TSI), which continuously activate thyroid hormone production independent of normal pituitary feedback. The result is a hypermetabolic state causing weight loss, tachycardia, heat intolerance, anxiety, tremor, and — in up to 50% of cases — Graves' ophthalmopathy (eye protrusion and orbital inflammation).
Standard therapy — antithyroid medications, radioactive iodine, or thyroidectomy — controls or eliminates thyroid hormone overproduction but does not address the underlying autoimmunity. Radioactive iodine ablation and surgery render the patient permanently hypothyroid, requiring lifelong levothyroxine. Recurrence after antithyroid drugs occurs in 50–70% of patients.
MSC therapy is being explored as an immune-modulating approach to Graves' disease — targeting the B-cell-driven TSI autoantibody production and the T-cell-mediated orbital inflammation of Graves' ophthalmopathy.
MSCs suppress B-cell differentiation into autoantibody-producing plasma cells — including those secreting the TSI antibodies that drive Graves' hyperthyroidism. Simultaneously, Treg expansion induced by MSC infusion promotes thyroid immune tolerance, potentially enabling reduction or cessation of antithyroid medication over time.
For Graves' ophthalmopathy specifically, MSC anti-inflammatory effects target the orbital fibroblast activation and T-cell-mediated inflammation driving proptosis and extraocular muscle disease. Published case reports and small series have documented TSI titer reduction and ophthalmopathy improvement in patients receiving MSC therapy.
True Regen coordinates thyroid function panel, TSI/TRAb antibody titers, and ophthalmology assessment (where applicable) before treatment, with repeat testing at 3, 6, and 12 months to track immunological response.
- Reduction in TSI/TRAb autoantibody titers
- Normalization of thyroid hormone levels
- Reduced antithyroid medication requirements
- Improvement in Graves' ophthalmopathy activity
- Reduced risk of relapse after antithyroid therapy discontinuation
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.